Our Company We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
Partnerships AbbVie: US co-development/commercialization collaboration (Ironwood records its share of LINZESS net profit/loss); ex-US partners market as LINZESS/CONSTELLA
Indications
irritable bowel syndrome with constipation (IBS-C)(Approved)
chronic idiopathic constipation (CIC)(Approved)
Status note Linaclotide; first FDA-approved GC-C agonist class. Majority of company revenue from US LINZESS sales; pediatric linaclotide programs referenced but undescribed.
Apraglutide
Phase 3 · ActiveModality: synthetic peptide analog (long-acting)
Target GLP-2
Partnerships VectivBio (acquired): origin; Asahi Kasei Therapeutics (AKTX): exclusive license for apraglutide in Japan (2022)
Indications
short bowel syndrome with intestinal failure (SBS-IF)(Phase 3)
Status note Next-generation long-acting synthetic peptide analog of GLP-2 for SBS patients dependent on parenteral support; confirmatory Phase 3 trial recruiting.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.